Incyte (INCY) Profit After Tax Growth (5y) (2015 - 2026)
Powered by 
Analysis
Incyte (INCY) Profit After Tax Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.31 Bn | 130.45 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.17 Bn | 77.17 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.25 Bn | 58.07 Bn | 1.37 Bn |
| 4 | Moderna | 58.27 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 40.01 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.26 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.37 Bn | 26.21 Bn | 358.27 Mn |
| 10 | Incyte | 25.53 Bn | 21.00 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.41% |
| Mar 31, 2026 | 41.47% |
| Dec 31, 2025 | 14.84% |
| Sep 30, 2025 | 97.30% |
| Jun 30, 2025 | 6.89% |
| Mar 31, 2025 | 17.29% |
| Dec 31, 2024 | 12.63% |
| Sep 30, 2024 | -3.66% |
| Jun 30, 2024 | -44.14% |
| Mar 31, 2024 | 10.63% |
| Dec 31, 2023 | 23.83% |
| Sep 30, 2023 | 42.47% |
| Jun 30, 2023 | 31.18% |
| Mar 31, 2023 | 20.38% |
| Dec 31, 2022 | 16.98% |
| Sep 30, 2022 | 25.62% |
| Jun 30, 2022 | 71.72% |
| Mar 31, 2022 | 17.11% |
| Dec 31, 2021 | 22.41% |
| Sep 30, 2021 | 53.14% |